Eli Lilly Stock-Based Compensation 2010-2025 | LLY

Eli Lilly stock-based compensation for the twelve months ending March 31, 2025 was $1.674B, a 5.32% increase year-over-year.

  • Eli Lilly annual stock-based compensation for 2024 was $0.646B, a 2.72% increase from 2023.
  • Eli Lilly annual stock-based compensation for 2023 was $0.629B, a 69.36% increase from 2022.
  • Eli Lilly annual stock-based compensation for 2022 was $0.371B, a 8.26% increase from 2021.

Eli Lilly Stock-Based Compensation 2010-2025 | LLY

  • Eli Lilly annual stock-based compensation for 2024 was $0.646B, a 2.72% increase from 2023.
  • Eli Lilly annual stock-based compensation for 2023 was $0.629B, a 69.36% increase from 2022.
  • Eli Lilly annual stock-based compensation for 2022 was $0.371B, a 8.26% increase from 2021.
Related Stocks
Company NameMarket
Cap
Johnson & Johnson (JNJ)$379.5B
AbbVie (ABBV)$306B
Novo Nordisk (NVO)$260.6B
Roche Holding AG (RHHBY)$248.1B
Novartis AG (NVS)$234.2B
Merck (MRK)$196.7B
Sanofi (SNY)$128.6B
Pfizer (PFE)$125.6B
Bayer (BAYRY)$23.7B
Innoviva (INVA)$1.1B